Evidence map›Paper›PMID 42471754›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Development and characterization of a novel TDP-43 positron emission tomography tracer: [

Chunfang A Xia, Mani Salarian, Christopher J Gartshore, Antonella Scaglione, Thomas Hayes, Shuanglong Liu, Hsiu-Ming Tsai, Javier Echavarren, Jose Maria Cid, Alessandra Matzeu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chunfang A XiaDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, San Diego, California, USA.
Mani SalarianDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, San Diego, California, USA.
Christopher J GartshoreDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, San Diego, California, USA.
Antonella ScaglioneNeuroscience Biomarkers, Johnson & Johnson, San Diego, California, USA.
Thomas HayesGlobal Discovery Chemistry, Johnson & Johnson, San Diego, California, USA.
Shuanglong LiuGlobal Discovery Chemistry, Johnson & Johnson, San Diego, California, USA.
Hsiu-Ming TsaiDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, San Diego, California, USA.
Javier EchavarrenGlobal Discovery Chemistry, Johnson & Johnson, Toledo, Spain.
Jose Maria CidGlobal Discovery Chemistry, Johnson & Johnson, Toledo, Spain.
Alessandra MatzeuPreclinical Sciences and Translational Safety, Johnson & Johnson, San Diego, California, USA.
A Katrin SzardeningsDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, San Diego, California, USA.

Funding

Johnson & Johnson
6 · The paper itself

Abstract

introductionNeurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and Alzheimer's disease (AD) are associated with TAR DNA-binding protein 43 (TDP-43) pathology. A positron emission tomography (PET) tracer targeting TDP-43 aggregates could improve early diagnosis and guide treatment development for TDP-43-related conditions.

methodsSpecific binding was evaluated using fluorescent labeling of compound, surface plasmon resonance (SPR), and autoradiography (ARG). Brain PET imaging in rats, nonhuman primate (NHP), and a disease mouse model was performed to characterize tracer pharmacokinetics and in vivo target binding.

resultsJNJ-TDP43-1 exhibited high binding affinity for pathological TDP-43 (K DISCUSSION: [

Indexed as

BrainDNA-Binding ProteinsPositron-Emission TomographyRadiopharmaceuticalsAnimalsDisease Models, AnimalFluorine RadioisotopesHumansMaleMiceRatsTDP-43 ProteinopathiesDNA-Binding ProteinsFluorine RadioisotopesRadiopharmaceuticalsTARDBP protein, human[18F]JNJ‐TDP43‐1amyotrophic lateral sclerosisfrontotemporal lobar degenerationlimbic‐predominant age‐related TDP‐43 encephalopathyneurodegenerative disorderspositron emission tomographyTDP‐43

Identifiers

PMID42471754
PMCPMC13380671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.